Prenuvo Secures $120M to Expand AI-Powered Technology & FDA-Cleared Health Assessments
The full-body MRI company seeks to advance and expand preventative healthcare offerings globally
Prenuvo, the full-body MRI company, has announced that it achieved $100 million in revenue last year and secured $120 million in funding to expand its AI-powered early detection technology further. The investment round was led by Forerunner Ventures, Left Lane Capital, and Felicis, the same backers behind Oura Health.
With newly secured FDA clearance, Prenuvo is launching a new body composition analysis this spring, alongside expanded brain and metabolic health assessments.
“Prenuvo is leading a movement to make proactive healthcare accessible and transformative for everyone,” said CEO Andrew Lacy. “We’re introducing a new approach to early detection that empowers individuals to take control of their health before symptoms emerge. This isn’t just about healthcare; it’s about reimagining how we approach health, using cutting-edge technology and world-class expertise to prevent disease and help people live longer, healthier lives.”
Prenuvo’s newly FDA-cleared AI-powered body composition analysis provides a non-invasive breakdown of visceral fat, subcutaneous fat, liver fat, muscle volumes, and key abdominal organs. The company is also introducing a next-generation brain health scan, offering critical data on cognitive function and early indicators of neurodegenerative diseases. Prenuvo is launching a comprehensive blood biomarker assessment, providing insights into metabolic, cardiovascular, hormonal, and immune health. These capabilities will first be available through Prenuvo Enhanced, a bundled offering launching in Silicon Valley, Los Angeles, and New York, with additional locations rolling out in the spring.
Prenuvo has surpassed 110,000 members and uncovered over 1.4 million personalized health insights. The company is scaling with 15 new clinics, including its first international locations in Europe and Australia.
“With only 2.5% of healthcare spending focused on preventative medicine, the US system waits for people to become sick before intervening,” said Brian O’Malley of Forerunner Ventures. “Consumers have grown tired of this and are responding with their own wallets. Prenuvo is the preeminent solution for a comprehensive understanding of one’s health, giving today’s patients unprecedented levels of knowledge to not just understand but proactively intervene in the challenges that arise as we all age. Longevity is the new luxury, and Prenuvo is democratizing access so that more can benefit from this.”